YolTech Therapeutics Raises $45 Million in Series B Financing Led by AstraZeneca-CICC
- Written by PR Newswire
SHANGHAI, Sept. 11, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotech company pioneering in vivo genome editing therapies, today announced the closing of its approximately $45 million Series B financing led by the AstraZeneca-CICC healthcare investment fund. The proceeds will support the advancement of YolTech's clinical programs...
